Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-091 in Healthy Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2025 Interim results presented in the Spyre Therapeutics media release.
16 Jun 2025 According to Spyre Therapeutics media release, the company announced that it will report interim results on Tuesday, June 17, 2025. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
13 Jan 2025 According to Spyre Therapeutics media release, the interim results expected in 2Q 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com